Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free BVS Stock Alerts

Bioventus (BVS) Financials

Bioventus logo
$10.68 +0.51 (+5.01%)
Closing price 04:00 PM Eastern
Extended Trading
$11.03 +0.35 (+3.27%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Bioventus

Annual Income Statements for Bioventus

This table shows Bioventus' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 6.85 16 19 -159 -156 -36 23
Consolidated Net Income / (Loss)		 6.30 15 9.59 -213 -196 -47 27
Net Income / (Loss) Continuing Operations		 8.11 15 11 -145 -121 -47 27
Total Pre-Tax Income 		9.69 16 9.49 -189 -121 -52 26
Total Operating Income		 31 21 12 -167 -82 -15 54
Total Gross Profit		 249 234 303 331 328 388 388
Total Revenue		 340 321 431 512 512 573 568
Operating Revenue		 - 321 431 512 512 573 568
Total Cost of Revenue		 91 88 128 181 184 185 180
Operating Cost of Revenue		 - 88 128 181 184 185 180
Total Operating Expenses		 218 212 291 498 410 403 334
Selling, General & Admin Expense		 198 193 254 332 304 344 314
Research & Development Expense		 11 11 19 24 13 14 12
Depreciation Expense		 7.91 7.44 8.36 9.75 8.84 7.65 5.73
Other Operating Expenses / (Income)		 - - 0.00 0.00 3.58 0.29 0.08
Impairment Charge		 0.00 0.00 5.67 125 79 36 0.00
Restructuring Charge		 0.58 0.56 2.49 6.78 0.84 -0.05 2.24
Other Special Charges / (Income)		 0.00 0.00 0.83 1.10 0.72 1.42 0.00
Total Other Income / (Expense), net		 -22 -5.32 -2.57 -22 -39 -37 -28
Interest Expense		 - - - - 0.00 0.00 0.33
Interest & Investment Income		 -22 -9.75 -1.11 -12 -41 -39 -26
Other Income / (Expense), net		 0.08 4.43 -1.46 -9.77 1.29 1.65 -1.45
Income Tax Expense		 1.58 1.19 -1.97 -44 0.09 -5.29 -1.57
Net Income / (Loss) Discontinued Operations		 -1.82 - -1.87 -69 -74 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.55 -1.69 -9.79 -55 -39 -11 4.54
Basic Earnings per Share		 $0.00 $0.00 ($0.15) ($2.59) ($2.49) ($0.56) $0.34
Weighted Average Basic Shares Outstanding		 0.00 0.00 45.47M 61.39M 62.65M 64.55M 66.62M
Diluted Earnings per Share		 $0.00 $0.00 ($0.15) ($2.59) ($2.49) ($0.56) $0.33
Weighted Average Diluted Shares Outstanding		 0.00 0.00 45.47M 61.39M 62.65M 64.55M 68.91M
Weighted Average Basic & Diluted Shares Outstanding		 - - 76.39M 78.05M 79.17M 81.94M 83.15M

Quarterly Income Statements for Bioventus

This table shows Bioventus' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025 9/27/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -3.68 -7.30 -6.10 -4.89 -26 -5.17 -0.16 -2.64 7.46 3.16 15
Consolidated Net Income / (Loss)		 -4.73 -8.79 -7.66 -6.38 -34 -5.85 -0.32 -3.32 9.27 4.01 17
Net Income / (Loss) Continuing Operations		 -4.73 -8.79 -7.66 -6.38 -34 -5.85 -0.32 -3.32 9.27 4.01 17
Total Pre-Tax Income 		-4.35 -8.19 -8.41 -5.47 -42 -5.26 0.23 -3.42 10 4.67 14
Total Operating Income		 6.75 2.42 1.17 4.93 -31 3.65 7.99 4.87 18 11 19
Total Gross Profit		 89 79 86 88 104 94 103 83 102 94 109
Total Revenue		 137 121 135 129 151 139 154 124 148 139 158
Operating Revenue		 137 121 135 129 151 139 154 124 148 139 158
Total Cost of Revenue		 48 42 49 41 48 45 51 41 46 44 49
Operating Cost of Revenue		 48 42 49 41 48 45 51 41 46 44 49
Total Operating Expenses		 82 76 85 83 135 90 95 78 84 83 89
Selling, General & Admin Expense		 75 70 78 79 97 81 87 74 79 79 83
Research & Development Expense		 3.40 3.02 3.26 2.63 4.21 3.84 3.25 3.01 3.17 2.92 3.01
Depreciation Expense		 2.29 2.32 2.10 1.76 2.06 2.07 1.77 1.59 1.44 1.40 1.30
Total Other Income / (Expense), net		 -11 -11 -9.57 -10 -10 -8.91 -7.76 -8.29 -8.06 -6.58 -5.34
Interest & Investment Income		 -11 -10 -10 -10 -9.92 -9.53 -9.00 -7.51 -7.49 -6.18 -5.31
Other Income / (Expense), net		 -0.51 -0.49 0.71 -0.06 -0.16 0.63 1.24 -0.78 -0.56 -0.08 -0.04
Income Tax Expense		 0.38 0.60 -0.75 0.91 -7.34 0.59 0.55 -0.10 1.04 0.66 -3.18
Net Income / (Loss) Attributable to Noncontrolling Interest		 -1.05 -1.49 -1.56 -1.49 -8.54 -0.68 -0.16 -0.69 1.81 0.85 2.56
Basic Earnings per Share		 ($0.06) ($0.12) ($0.07) ($0.08) ($0.40) ($0.08) ($0.01) ($0.04) $0.11 $0.05 $0.22
Weighted Average Basic Shares Outstanding		 62.55M 62.82M 62.65M 63.38M 64.06M 65.26M 64.55M 66.01M 66.50M 66.92M 66.62M
Diluted Earnings per Share		 ($0.06) ($0.12) ($0.07) ($0.08) ($0.40) ($0.08) ($0.01) ($0.04) $0.11 $0.05 $0.21
Weighted Average Diluted Shares Outstanding		 62.55M 62.82M 62.65M 63.38M 64.06M 65.26M 64.55M 66.01M 68.54M 68.84M 68.91M
Weighted Average Basic & Diluted Shares Outstanding		 78.58M 78.75M 79.17M 79.61M 80.97M 81.15M 81.94M 82.14M 82.68M 82.76M 83.15M

Annual Cash Flow Statements for Bioventus

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 22 22 12 -67 5.13 4.62 9.66
Net Cash From Operating Activities		 41 72 23 -14 15 39 75
Net Cash From Continuing Operating Activities		 43 72 23 -11 18 39 75
Net Income / (Loss) Continuing Operations		 8.11 15 11 -145 -121 -47 27
Consolidated Net Income / (Loss)		 6.30 15 9.59 -213 -196 -47 27
Net Income / (Loss) Discontinued Operations		 -1.82 - -1.87 -69 -74 0.00 0.00
Depreciation Expense		 30 29 35 55 57 50 47
Non-Cash Adjustments To Reconcile Net Income		 16 12 0.15 153 84 49 14
Changes in Operating Assets and Liabilities, net		 -12 17 -23 -75 -3.13 -13 -14
Net Cash From Discontinued Operating Activities		 -1.83 -0.40 0.00 -2.13 -2.17 0.00 0.00
Net Cash From Investing Activities		 -7.91 -21 -284 -116 16 23 -3.25
Net Cash From Continuing Investing Activities		 -7.91 -21 -284 -12 27 23 -3.25
Purchase of Property, Plant & Equipment		 -2.34 -17 -14 -1.48 -7.36 -1.01 -2.56
Acquisitions		 0.43 -4.09 -270 -10 0.00 -0.71 0.00
Other Investing Activities, net		 - 0.00 0.00 -0.08 35 25 -0.69
Net Cash From Discontinued Investing Activities		 0.00 0.17 0.00 -105 -12 0.00 0.00
Net Cash From Financing Activities		 -11 -30 273 62 -27 -55 -62
Net Cash From Continuing Financing Activities		 -11 -30 273 62 -27 -55 -62
Repayment of Debt		 -200 -59 -112 -45 -91 -62 -121
Issuance of Debt		 198 49 277 105 64 0.00 77
Issuance of Common Equity		 0.00 0.00 109 5.82 0.78 2.44 2.07
Other Financing Activities, net		 - 0.00 0.00 -3.35 0.00 4.50 -20
Effect of Exchange Rate Changes		 -0.10 0.59 -0.23 0.52 0.63 -2.56 0.37

Quarterly Cash Flow Statements for Bioventus

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025 9/27/2025 12/31/2025
Net Change in Cash & Equivalents		 -18 -2.56 10 -12 6.82 11 -1.49 -19 10 9.25 9.07
Net Cash From Operating Activities		 11 -8.32 10 -6.01 15 10 19 -19 26 30 38
Net Cash From Continuing Operating Activities		 11 -8.32 10 -6.01 15 10 19 -19 26 30 38
Net Income / (Loss) Continuing Operations		 -4.73 -8.79 -7.66 -6.38 -32 -5.42 -0.32 -3.32 9.27 4.01 17
Consolidated Net Income / (Loss)		 -4.73 -8.79 -7.66 -6.38 -32 -5.42 -0.32 -3.32 9.27 4.01 17
Depreciation Expense		 15 14 12 12 13 12 12 12 12 11 12
Non-Cash Adjustments To Reconcile Net Income		 -2.34 2.70 1.83 2.39 36 3.35 4.53 2.90 3.71 3.63 3.73
Changes in Operating Assets and Liabilities, net		 3.27 -16 3.73 -14 -1.96 0.11 2.70 -31 0.90 11 5.23
Net Cash From Investing Activities		 34 -2.04 -0.59 -1.00 -0.08 -0.06 24 -0.83 -1.37 -0.47 -0.58
Net Cash From Continuing Investing Activities		 34 -2.04 -0.59 -1.00 -0.08 -0.06 24 -0.83 -1.37 -0.47 -0.58
Purchase of Property, Plant & Equipment		 -1.40 -2.04 -0.37 -0.29 -0.08 -0.06 -0.57 -0.83 -0.68 -0.47 -0.58
Net Cash From Financing Activities		 -62 8.23 -0.01 -4.24 -7.85 0.36 -43 0.95 -15 -20 -28
Net Cash From Continuing Financing Activities		 -62 8.23 -0.01 -4.24 -7.85 0.36 -43 0.95 -15 -20 -28
Repayment of Debt		 -60 -7.17 -3.83 -4.42 -8.45 -0.19 -50 -5.20 -5.21 -81 -30
Issuance of Common Equity		 0.14 0.40 0.16 0.18 0.61 0.55 1.10 0.15 1.32 0.10 0.51
Other Financing Activities, net		 -1.99 - 3.66 0.00 - - 5.68 -9.00 -11 -0.71 0.70
Effect of Exchange Rate Changes		 0.24 -0.44 0.37 -0.54 -0.42 0.47 -2.06 0.43 0.20 -0.39 0.13

Annual Balance Sheets for Bioventus

This table presents Bioventus' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 494 1,226 1,373 811 728 684
Total Current Assets		 212 263 273 268 276 273
Cash & Equivalents		 87 44 30 37 42 51
Accounts Receivable		 88 125 136 123 127 128
Inventories, net		 29 62 85 91 92 82
Prepaid Expenses		 7.55 27 19 17 14 11
Plant, Property, & Equipment, net		 6.88 23 27 37 27 22
Total Noncurrent Assets		 276 940 1,073 506 421 383
Long-Term Investments		 19 29 2.62 3.14 1.89 2.29
Goodwill		 50 148 7.46 7.46 7.46 7.46
Intangible Assets		 192 695 640 482 405 368
Other Noncurrent Operating Assets		 15 67 17 13 6.51 5.12
Total Liabilities & Shareholders' Equity		 494 1,226 1,373 811 728 684
Total Liabilities		 350 692 960 590 542 455
Total Current Liabilities		 123 181 304 175 210 160
Short-Term Debt		 15 18 33 28 47 15
Accounts Payable		 4.42 17 37 23 24 11
Accrued Expenses		 88 131 112 120 136 130
Other Current Liabilities		 3.93 3.56 3.61 4.82 3.92 4.21
Total Noncurrent Liabilities		 228 511 656 414 332 295
Long-Term Debt		 173 340 385 367 308 279
Noncurrent Deferred & Payable Income Tax Liabilities		 3.36 134 2.25 1.21 0.56 0.43
Other Noncurrent Operating Liabilities		 22 38 40 46 23 15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 144 534 412 221 186 228
Total Preferred & Common Equity		 0.00 459 325 174 148 184
Total Common Equity		 0.00 459 325 174 148 184
Common Stock		 0.00 465 491 494 508 521
Retained Earnings		 0.00 -6.60 -165 -322 -358 -335
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.18 -0.11 0.79 -2.57 -1.90
Noncontrolling Interest		 144 75 87 48 38 44

Quarterly Balance Sheets for Bioventus

This table presents Bioventus' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 10/1/2022 4/1/2023 7/1/2023 9/30/2023 3/30/2024 6/29/2024 9/28/2024 3/29/2025 6/28/2025 9/27/2025
Total Assets		 1,398 887 837 811 794 792 769 691 707 702
Total Current Assets		 271 309 261 249 266 309 299 249 275 281
Cash & Equivalents		 34 47 29 27 25 32 43 23 33 42
Accounts Receivable		 132 119 120 113 126 137 122 118 132 130
Inventories, net		 77 88 96 98 97 88 90 94 96 96
Prepaid Expenses		 28 17 15 12 18 24 17 14 13 12
Plant, Property, & Equipment, net		 0.00 37 42 40 35 32 29 26 25 23
Total Noncurrent Assets		 1,127 542 534 522 494 451 441 416 407 398
Long-Term Investments		 13 2.62 6.54 6.86 3.21 2.09 1.93 1.76 1.69 2.27
Goodwill		 15 7.46 7.46 7.46 7.46 7.46 7.46 7.46 7.46 7.46
Intangible Assets		 1,056 516 505 493 471 425 415 396 387 377
Noncurrent Deferred & Refundable Income Taxes		 0.00 - - - - 6.88 7.40 4.75 4.75 4.75
Other Noncurrent Operating Assets		 43 16 15 14 12 10 9.78 6.63 6.23 5.83
Total Liabilities & Shareholders' Equity		 1,398 887 837 811 794 792 769 691 707 702
Total Liabilities		 1,019 647 604 585 577 603 583 506 505 494
Total Current Liabilities		 288 196 179 161 173 231 211 175 186 162
Short-Term Debt		 31 41 11 20 36 57 58 48 43 11
Accounts Payable		 19 33 41 18 19 24 17 19 24 27
Accrued Expenses		 117 116 122 119 114 140 129 103 114 119
Other Current Liabilities		 121 6.15 4.67 4.73 4.81 9.74 8.15 4.36 4.41 4.41
Total Noncurrent Liabilities		 731 451 425 424 403 372 371 331 320 333
Long-Term Debt		 393 404 375 375 355 345 345 309 298 311
Noncurrent Deferred & Payable Income Tax Liabilities		 159 0.35 0.00 0.00 1.29 0.00 0.00 0.61 0.65 0.79
Other Noncurrent Operating Liabilities		 178 46 50 49 47 27 26 22 21 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 379 240 233 226 217 189 187 185 201 207
Total Preferred & Common Equity		 343 189 183 178 171 151 149 148 161 166
Total Common Equity		 343 189 183 178 171 151 149 148 161 166
Common Stock		 478 493 491 493 497 501 503 511 515 518
Retained Earnings		 -133 -304 -308 -315 -326 -350 -355 -360 -353 -350
Accumulated Other Comprehensive Income / (Loss)		 -1.34 0.41 0.66 0.40 0.33 -0.02 0.45 -2.06 -0.77 -1.84
Noncontrolling Interest		 36 52 50 49 46 38 38 37 40 41

Annual Metrics And Ratios for Bioventus

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 75,224,819.00 - - - 82,763,214.00
DEI Adjusted Shares Outstanding		 0.00 0.00 75,224,819.00 - - - 82,763,214.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.26 - - - 0.27
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 26 20 15 -117 -57 -8.39 57
Return On Investment Capital (ROIC_SIMPLE)		 - - - -14.10% -9.29% -1.55% 10.96%
Earnings before Interest and Taxes (EBIT)		 31 26 11 -177 -80 -10 53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 62 54 45 -122 -23 39 100
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -207 -572 -41 104 75 87
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 226 813 737 576 493 463
Increase / (Decrease) in Invested Capital		 0.00 226 587 -76 -161 -83 -29
Book Value per Share		 $0.00 $0.00 $6.10 $4.18 $2.20 $1.82 $2.22
Tangible Book Value per Share		 $0.00 ($30.18) ($5.10) ($4.14) ($4.02) ($3.26) ($2.32)
Total Capital		 0.00 333 891 830 616 541 522
Total Debt		 0.00 188 358 418 395 355 294
Total Long-Term Debt		 0.00 173 340 385 367 308 279
Net Debt		 0.00 82 279 385 355 312 240
Capital Expenditures (CapEx)		 2.34 17 14 1.48 7.36 1.01 2.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 17 51 -29 83 71 76
Debt-free Net Working Capital (DFNWC)		 0.00 104 100 1.61 120 112 127
Net Working Capital (NWC)		 0.00 89 82 -31 93 65 112
Net Nonoperating Expense (NNE)		 20 4.92 4.97 96 138 35 30
Net Nonoperating Obligations (NNO)		 0.00 82 279 324 355 307 235
Total Depreciation and Amortization (D&A)		 30 29 35 55 57 50 47
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.15) ($2.59) ($2.49) ($0.52) $0.34
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 45.47M 61.39M 62.65M 64.55M 66.62M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.15) ($2.59) ($2.49) ($0.52) $0.33
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 45.47M 61.39M 62.65M 64.55M 68.91M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 76.39M 78.05M 79.17M 81.94M 83.15M
Normalized Net Operating Profit after Tax (NOPAT)		 27 20 15 -24 -1.09 18 39
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Bioventus

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025 9/27/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - 81,943,605.00 82,144,347.00 82,679,040.00 82,763,214.00
DEI Adjusted Shares Outstanding		 - - - - - - - 81,943,605.00 82,144,347.00 82,679,040.00 82,763,214.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -0.03 0.09 0.04 0.18
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 4.73 1.69 0.82 3.73 -21 2.85 -11 3.41 17 9.65 24
Return On Investment Capital (ROIC_SIMPLE)		 - - 0.13% - - - -2.02% 0.63% 3.04% 1.82% 4.57%
Earnings before Interest and Taxes (EBIT)		 6.24 1.92 1.87 5.26 -30 4.70 9.23 4.09 18 11 19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 21 16 14 17 -16 17 22 16 30 23 31
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 196 170 162 60 5.74 46 72 66 66 69 53
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 583 587 576 580 557 545 493 517 508 485 463
Increase / (Decrease) in Invested Capital		 -191 -169 -161 -56 -26 -43 -83 -63 -49 -59 -29
Book Value per Share		 $2.34 $2.26 $2.20 $2.16 $1.90 $1.84 $1.82 $1.81 $1.96 $2.01 $2.22
Tangible Book Value per Share		 ($4.21) ($4.11) ($4.02) ($3.88) ($3.53) ($3.38) ($3.26) ($3.11) ($2.84) ($2.65) ($2.32)
Total Capital		 619 621 616 609 591 590 541 542 543 530 522
Total Debt		 386 395 395 391 402 403 355 357 341 323 294
Total Long-Term Debt		 375 375 367 355 345 345 308 309 298 311 279
Net Debt		 350 361 355 363 368 358 312 332 307 278 240
Capital Expenditures (CapEx)		 1.40 2.04 0.37 0.29 0.08 0.06 0.57 0.83 0.68 0.47 0.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 63 81 83 103 103 102 71 100 100 88 76
Debt-free Net Working Capital (DFNWC)		 93 108 120 128 135 145 112 123 133 130 127
Net Working Capital (NWC)		 82 89 93 93 77 87 65 75 90 119 112
Net Nonoperating Expense (NNE)		 9.46 10 8.47 9.71 12 8.27 -11 6.73 7.24 5.65 6.54
Net Nonoperating Obligations (NNO)		 350 361 355 363 368 358 307 332 307 278 235
Total Depreciation and Amortization (D&A)		 15 14 12 12 13 12 12 12 12 11 12
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.06) ($0.12) ($0.07) ($0.07) ($0.37) ($0.07) ($0.01) ($0.04) $0.11 $0.05 $0.22
Adjusted Weighted Average Basic Shares Outstanding		 62.55M 62.82M 62.65M 63.38M 64.06M 65.26M 64.55M 66.01M 66.50M 66.92M 66.62M
Adjusted Diluted Earnings per Share		 ($0.06) ($0.12) ($0.07) ($0.07) ($0.37) ($0.07) ($0.01) ($0.04) $0.11 $0.05 $0.21
Adjusted Weighted Average Diluted Shares Outstanding		 62.55M 62.82M 62.65M 63.38M 64.06M 65.26M 64.55M 66.01M 68.54M 68.84M 68.91M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 78.58M 78.75M 79.17M 79.61M 80.97M 81.15M 81.94M 82.14M 82.68M 82.76M 83.15M
Normalized Net Operating Profit after Tax (NOPAT)		 5.33 1.61 0.97 3.94 1.96 4.61 7.52 3.41 17 9.65 14
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Below is a concise, trend-focused summary of Bioventus (BVS) quarterly results from the last four years, based on the provided income statements, cash flow statements, and balance sheets. The bullets highlight the most important points for retail investors.

  • Q4 2025 revenue reached $157.9 million, up from $153.6 million in Q4 2024, indicating year-over-year growth.
  • Q4 2025 gross profit was $108.782 million, with a gross margin of about 68.9% (108.782 / 157.9), reflecting solid profitability at the gross level.
  • Q4 2025 operating income was $19.486 million, an operating margin near 12.3%, signaling meaningful operating profitability.
  • Q4 2025 net income attributable to common shareholders was $14.755 million, a positive quarterly bottom line.
  • Q4 2025 cash flow from continuing operating activities was $37.968 million, indicating strong cash generation from core operations.
  • Q4 2025 net change in cash and equivalents was a positive $9.074 million, showing overall cash generation despite financing/investing activity.
  • Balance sheet snapshot (Q3 2025): Total assets about $701.593 million; total liabilities about $494.338 million; total equity and noncontrolling interests about $207.255 million.
  • Net cash from financing activities in Q4 2025 was negative $28.447 million, indicating cash outflows from financing activities (e.g., debt repayments and other financing).
  • Notable one-off impairment charges in some quarters (e.g., $124.697 million impairment in Q3 2023), which weigh on earnings in those periods.
  • Profitability has been volatile, with quarters showing net losses (e.g., Q1 2025 continuing net income of -$3.322 million; Q3 2023 continuing net income of -$8.791 million), suggesting earnings variability.
05/05/26 07:34 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Bioventus' Financials

When does Bioventus' fiscal year end?

According to the most recent income statement we have on file, Bioventus' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Bioventus' net income changed over the last 6 years?

Bioventus' net income appears to be on an upward trend, with a most recent value of $27.27 million in 2025, rising from $6.30 million in 2019. The previous period was -$47.05 million in 2024. Find out what analysts predict for Bioventus in the coming months.

What is Bioventus' operating income?
Bioventus' total operating income in 2025 was $53.98 million, based on the following breakdown:
  • Total Gross Profit: $388.16 million
  • Total Operating Expenses: $334.18 million
How has Bioventus' revenue changed over the last 6 years?

Over the last 6 years, Bioventus' total revenue changed from $340.14 million in 2019 to $568.09 million in 2025, a change of 67.0%.

How much debt does Bioventus have?

Bioventus' total liabilities were at $455.11 million at the end of 2025, a 16.1% decrease from 2024, and a 29.9% increase since 2020.

How much cash does Bioventus have?

In the past 5 years, Bioventus' cash and equivalents has ranged from $30.19 million in 2022 to $86.84 million in 2020, and is currently $51.24 million as of their latest financial filing in 2025.

How has Bioventus' book value per share changed over the last 6 years?

Over the last 6 years, Bioventus' book value per share changed from 0.00 in 2019 to 2.22 in 2025, a change of 222.5%.


Related Companies

Financial statements for NASDAQ:BVS last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel